

# Olympus, Ultivue comarketing agreement

written by CAP TODAY  
February 19, 2020

February 2020—Olympus and Ultivue, a developer of tissue biomarker identification and quantification assays for translational research, have entered into a comarketing agreement. The partnership will provide a solution for fluorescent multiplexing by combining the Olympus Slideview VS200 automated slide scanner with Ultivue's proprietary InSituPlex DNA barcoding and staining technology to provide quantitative colocalization analysis in fluorescent whole slide images.

As part of the agreement, Ultivue evaluated the Olympus VS120 and next-generation VS200 slide scanners to qualify the systems and specific configurations optimized for use with Ultivue's UltiMapper kits.



“We evaluated the Olympus VS120, and it exceeded the high standards for scanner compatibility with our UltiMapper kits,” Philippe Mourere, senior vice president of commercial operations at Ultivue, said in a press release. “Using the UltiMapper optimized filter set, the scanner produced high-quality images with even illumination, seamless stitching across whole tissue sections, and no observed bleed-through signal. The scanning speed of the VS120 and higher speed of the VS200 slide scanner corresponds to or exceeds the demand of high-throughput users.”

In a separate release, Olympus announced the U.S. launch of the ScanR high-content screening station, a modular microscope-based imaging platform that provides fully automated image acquisition and data analysis of biological samples through deep-learning technology. The system is designed for multiwell plates, slides, and custom-built arrays. The learning capacity of ScanR AI aims to reduce photobleaching and improve acquisition speed, measurement sensitivity, and accuracy, facilitating longer observations with reduced influence on cell viability.

[Olympus](http://Olympus.com), 484-896-5000

